On Friday 12 June at 13:00, Eske Nøhr Glud defends his PhD dissertation entitled “Development of Liquid Biomarkers for Diagnosis and Prognosis in Prostate Cancer”. 

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy among men in the Western world. In Denmark alone, more than 4,000 men are diagnosed every year. A major clinical challenge in the early-stage setting is optimizing the balance between overdiagnosis and overtreatment of indolent disease, while ensuring that aggressive cancers, considered clinically significant, are accurately detected at an early stage allowing for curatively intended treatment. As the disease progresses the clinical challenge changes. In castration resistant prostate cancer, characterized by resistance to androgen deprivation therapy, the disease is associated with rapid progression and poor survival. Improved risk-stratification of castration resistant prostate cancer patients is needed to identify patients with stable disease that can safely continue on standard therapy, while patients at high risk of progression could benefit from alternative therapeutic strategies.

The summary is written by the PhD student.

The defence is public and takes place in the MOMA auditorium, Aarhus University. Please see the press release for more information. 

Contact

PhD student Eske N. Glud
Mail: eske.glud@clin.au.dk 
Phone: +45 29897865

Read full press release